ARS Pharmaceuticals, Inc. SPRY Financing Liability In Accounts Receivable
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept spry:FinancingLiabilityInAccountsReceivable.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s financing liability in accounts receivable.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s financing liability in accounts receivable?
- ARS Pharmaceuticals, Inc. (SPRY) reported financing liability in accounts receivable of $2.53M in Q1 2026.